Is Sanara MedTech Inc. (SMTI) a Buy, Sell, or Hold?
NASDAQ : SMTI
Sanara MedTech Inc.
$34.38 USD
$0.13 (0.38%)
- Volume
- 365.72K
- Average Volume
- 113.26K
- Market Capitalization
- $316.06M
- P/E Ratio
- -9.24
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $35.95
- Year Low
- $16.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.58
Company Overview
NASDAQ
Seth D. Yon
Medical - Instruments & Supplies
Healthcare
SMTI
108
US
USD
Liquidity Metrics
6.11
2.58
2.30
1.23
0.00
Sales & Valuation
$103.12M
2.88
37.80
70.17
0.52
Profitability
-$4.36
-$37.56M
-29.15%
-0.24%
-473.55%
-86.65%
P/E Metrics
-9.24
0.03
0.03
Analyst Price Target & Rating
$35.00
$35.00
$35.00
1/5
3 Analysts
-1.77%
Financial Health Scores
3.63
4/9
$17.5M
$69.28M
$62.26M
$5.35M
Key Metrics (TTM)
$349.63M
3.25
41.98
2.28
-246.44%
15.14%
-11.26%
1.07%
131 days
Company Executives
| Name | Title |
|---|---|
| Jacob A. Waldrop | Chief Operating Officer |
| Tyler Palmer | Chief Corporate Development & Strategy Officer |
| Ashley Mackey | Principal Accounting Officer |
| Elizabeth Taylor | Chief Financial Officer |
| Bill Fitzgerald | Chief Compliance Officer |
| Tricia Matteson | Vice President of Marketing |
| Nina Bionda | Chief R&D Officer |
| Ronald T. Nixon | Executive Chairman |
| Seth Yon | President, Chief Executive Officer & Director |
| Suresh V. Muppalla | President & Chief Executive Officer of THP |
Poll Results
No votes yet today — be the first to share your view!
About Sanara MedTech Inc. (NASDAQ:SMTI) Stock
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective a ... gainst both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates
2026-08-11 20:11:04
Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.23 per share a year ago.
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
2026-08-11 16:10:00
FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the second quarter ended June 30, 2026.
2026-08-06 11:31:00
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
2026-08-05 14:00:00
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--FBRX, LXFR, SMTI, and MKTX PR Newswire
2026-08-04 12:35:00
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
2026-08-04 11:22:00
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Are MKTX, SMTI, LPSN Obtaining Fair Deals for their Shareholders?
2026-08-03 19:38:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-08-03 16:19:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this c.
Frequently Asked Questions
-
What is the current Sanara MedTech Inc. (SMTI) stock price?
-
Sanara MedTech Inc.(NASDAQ:SMTI) stock price is $34.38 in the last trading session. During the trading session, SMTI stock reached the peak price of $35.95 while $16.05 was the lowest point it dropped to. The percentage change in SMTI stock occurred in the recent session was 0.38% while the dollar amount for the price change in SMTI stock was $0.13.
-
SMTI's industry and sector of operation?
-
The NASDAQ listed SMTI is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of SMTI?
-
Jacob A. Waldrop | Chief Operating Officer
Tyler Palmer | Chief Corporate Development & Strategy Officer
Ashley Mackey | Principal Accounting Officer
Elizabeth Taylor | Chief Financial Officer
Bill Fitzgerald | Chief Compliance Officer -
How many employees does SMTI have?
-
Number of SMTI employees currently stands at 108. SMTI operates from 1200 Summit Avenue, Fort Worth, TX 76102, US.
-
Link for SMTI official website?
-
Official Website of SMTI is: https://sanaramedtech.com
-
How do I contact SMTI?
-
SMTI could be contacted at phone #817 529 2300 and can also be accessed through its website. SMTI operates from 1200 Summit Avenue, Fort Worth, TX 76102, US.
-
How many shares of SMTI are traded daily?
-
The average number of SMTI shares traded daily for last 3 months was 113.26K.
-
What is the market cap of SMTI currently?
-
The market value of SMTI currently stands at $316.06M with its latest stock price at $34.38